{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:20Z","timestamp":1793422640558,"version":"4.5.0"},"reference-count":25,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 CA215110"],"award-info":[{"award-number":["K12 CA215110"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA121974"],"award-info":[{"award-number":["P50 CA121974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA216846"],"award-info":[{"award-number":["R01 CA216846"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA227472"],"award-info":[{"award-number":["R01 CA227472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA193200-5"],"award-info":[{"award-number":["T32 CA193200-5"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have dramatically improved survival in patients with cancer but are often accompanied by severe immune-related adverse events (irAEs), which can sometimes be irreversible. Insulin-dependent diabetes is a rare, but life-altering irAE. Our purpose was to determine whether recurrent somatic or germline mutations are observed in patients who develop insulin-dependent diabetes as an irAE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed RNA and whole exome sequencing on tumors from 13 patients who developed diabetes due to ICI exposure (ICI-induced diabetes mellitus, ICI-DM) compared with control patients who did not develop diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In tumors from ICI-DM patients, we did not find differences in expression of conventional type 1 diabetes autoantigens, but we did observe significant overexpression of ORM1, PLG, and G6PC, all of which have been implicated in type 1 diabetes or are related to pancreas and islet cell function. Interestingly, we observed a missense mutation in NLRC5 in tumors of 9 of the 13 ICI-DM patients that was not observed in the control patients treated with the same drugs for the same cancers. Germline DNA from the ICI-DM patients was sequenced; all <jats:italic>NLRC5<\/jats:italic> mutations were germline. The prevalence of <jats:italic>NLRC5<\/jats:italic> germline variants was significantly greater than the general population (p=5.98\u00d710<jats:sup>\u22126<\/jats:sup>). Although NLRC5 is implicated in development of type 1 diabetes, germline <jats:italic>NLRC5<\/jats:italic> mutations were not found in public databases from patients with type 1 diabetes, suggesting a different mechanism of insulin-dependent diabetes in immunotherapy-treated patients with cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Validation of the <jats:italic>NLRC5<\/jats:italic> mutation as a potential predictive biomarker is warranted, as it might improve patient selection for treatment regimens. Furthermore, this genetic alteration suggests potential mechanisms of islet cell destruction in the setting of checkpoint inhibitor therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-006570","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T07:56:40Z","timestamp":1678435000000},"page":"e006570","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1136","volume":"11","author":[{"given":"Jasmine I","family":"Caulfield","sequence":"first","affiliation":[{"name":"Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Aizenbud","sequence":"additional","affiliation":[{"name":"Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luisa","family":"Perdigoto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Meffre","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Jilaveanu","sequence":"additional","affiliation":[{"name":"Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika A","family":"Michalek","sequence":"additional","affiliation":[{"name":"Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S","family":"Rich","sequence":"additional","affiliation":[{"name":"Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yariv","family":"Aizenbud","sequence":"additional","affiliation":[{"name":"Department of Mathematics, Program in Applied Mathematics, Yale University, New Haven, Connecticut, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebowale","family":"Adeniran","sequence":"additional","affiliation":[{"name":"Pathology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan C","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Austin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-9873","authenticated-orcid":false,"given":"Harriet","family":"Kluger","sequence":"additional","affiliation":[{"name":"Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2025100309243747000_11.3.e006570.1","doi-asserted-by":"crossref","first-page":"990367","DOI":"10.3389\/fonc.2022.990367","article-title":"Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance","volume":"12","author":"Schoenfeld","year":"2022","journal-title":"Front Oncol"},{"key":"2025100309243747000_11.3.e006570.2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.877434","article-title":"Risk of adverse events in cancer patients receiving nivolumab with ipilimumab: a meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"2025100309243747000_11.3.e006570.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"2025100309243747000_11.3.e006570.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349"},{"key":"2025100309243747000_11.3.e006570.5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"2025100309243747000_11.3.e006570.6","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1471-P"},{"key":"2025100309243747000_11.3.e006570.7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2025100309243747000_11.3.e006570.8","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.6.4072-4078.2001"},{"key":"2025100309243747000_11.3.e006570.9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and glialcam","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"2025100309243747000_11.3.e006570.10","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.021"},{"key":"2025100309243747000_11.3.e006570.11","doi-asserted-by":"crossref","unstructured":"Ohguro H , Nakazawa M . n.d. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol;514:109\u201324.","DOI":"10.1007\/978-1-4615-0121-3_7"},{"key":"2025100309243747000_11.3.e006570.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100309243747000_11.3.e006570.13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-pharmtox-010919-023451","article-title":"Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure","volume":"61","author":"Waliany","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025100309243747000_11.3.e006570.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0533-0"},{"key":"2025100309243747000_11.3.e006570.15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IIO.0000000000000434","article-title":"Cancer immunotherapy and uveitis: balancing anti-tumor immunity and ocular autoimmunity","volume":"62","author":"Rali","year":"2022","journal-title":"Int Ophthalmol Clin"},{"key":"2025100309243747000_11.3.e006570.16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From fastq data to high\u2010confidence variant calls: the genome analysis toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"CP in Bioinformatics"},{"key":"2025100309243747000_11.3.e006570.17","doi-asserted-by":"publisher","DOI":"10.1002\/path.2440"},{"key":"2025100309243747000_11.3.e006570.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2014.12.004"},{"key":"2025100309243747000_11.3.e006570.19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.1.308"},{"key":"2025100309243747000_11.3.e006570.20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0410-248"},{"key":"2025100309243747000_11.3.e006570.21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41588-021-00880-5","article-title":"Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes","volume":"53","author":"Robertson","year":"2021","journal-title":"Nat Genet"},{"key":"2025100309243747000_11.3.e006570.22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-021-03552-w","article-title":"Interpreting type 1 diabetes risk with genetics and single-cell epigenomics","volume":"594","author":"Chiou","year":"2021","journal-title":"Nature"},{"key":"2025100309243747000_11.3.e006570.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183908","article-title":"Comparative quantitative proteomic analysis of disease stratified laser captured microdissected human islets identifies proteins and pathways potentially related to type 1 diabetes","volume":"12","author":"Nyalwidhe","year":"2017","journal-title":"PLoS ONE"},{"key":"2025100309243747000_11.3.e006570.24","doi-asserted-by":"crossref","unstructured":"Szymczak F , Alvelos MI , Mar\u00edn-Ca\u00f1as S , et al . Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic \u03b2 cells. Sci Adv 2022;8. doi:10.1126\/sciadv.abn5732","DOI":"10.1126\/sciadv.abn5732"},{"key":"2025100309243747000_11.3.e006570.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00709-6"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:24:43Z","timestamp":1759508683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2022-006570"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006570","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}